NAGE
Niagen Bioscience Inc
NAGE offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
NVO
Novo Nordisk A/S
NVO has the edge over NAGE overall, supported by stronger fundamentals and lower modeled downside.
NAGE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Strong |
NAGE's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NAGE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $2.05 | -3.7% |
| Current | 18x | $2.13 | — |
| Fair | 27x | $3.30 | +55% |
| Expensive | 79x | $9.47 | +345% |
| Forward | 217x | $2.13 | — |
Historical ranges are pointers, not guarantees.
NAGE's PE is in its cheap range at 18x. Analysts expect earnings to fall, which would put today's price at 217x next year's earnings, in its expensive range.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over NAGE in the historical PE scenario, which offers more potential upside but is not a forecast.
NAGE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NAGE's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over NAGE on the outlook, with more favorable earnings and revenue expectations.
NAGE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | -92% |
| Q3 2026 | $0.12 | -52% |
| Q2 2026 | $0.18 | -18% |
| Q1 2026 | $0.21 | +17% |
| Q4 2025 | $0.20 | +82% |
| Q3 2025 | $0.25 | +2400% |
| Q2 2025 | $0.22 | +$0.24 |
| Q1 2025 | $0.18 | +$0.23 |
| Q4 2024 | $0.11 | +$0.18 |
NAGE's earnings per share have fallen from their peak: $0.12 over the past year, against $0.25 in late 2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NAGE on earnings, with more consistent year-over-year improvement.
NAGE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.2M | -20% |
| Q2 2026 | $29.8M | -4.3% |
| Q1 2026 | $31.5M | +3.3% |
| Q4 2025 | $33.8M | +16% |
| Q3 2025 | $34M | +33% |
| Q2 2025 | $31.1M | +37% |
| Q1 2025 | $30.5M | +38% |
| Q4 2024 | $29.1M | +37% |
NAGE's revenue fell from its 2025 peak and has held roughly level since: $27M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.8% | -18 points |
| Q2 2026 | 2.4% | -7.9 points |
| Q1 2026 | 5% | -11 points |
| Q4 2025 | 12% | -12 points |
| Q3 2025 | 12% | +6.2 points |
| Q2 2025 | 10% | +11 points |
| Q1 2025 | 16% | +19 points |
| Q4 2024 | 24% | +25 points |
NAGE's operating margin was −5.8% last quarter, down 18 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NAGE on profitability, with a higher operating margin.
NAGE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6M | -29% |
| Q2 2026 | $2.8M | +122% |
| Q1 2026 | -$1.2M | -115% |
| Q4 2025 | $679K | -92% |
| Q3 2025 | $3.7M | +5.6% |
| Q2 2025 | $1.3M | +$1.5M |
| Q1 2025 | $7.9M | +2572% |
| Q4 2024 | $8.6M | +1222% |
NAGE still generates free cash flow, though less than at its 2024 peak: $5M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
NAGE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -3.4M shares |
| 1 year | -8.6% | -7.5M shares |
| 3 years | +5.5% | +4.1M shares |
| 5 years | +16% | +10.9M shares |
| Available history | +28% | +17.5M shares |
NAGE has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $2.8M |
| Q1 2026 | $2.4M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NAGE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -11.9x | Net Cash |
| Q2 2026 | -5.8x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -3.8x | Net Cash |
| Q3 2025 | -3.2x | Net Cash |
| Q2 2025 | -3.5x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -5.2x | Net Cash |
NAGE has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NAGE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 3.5 | Oversold |
NAGE's weekly RSI is 23 (oversold) and its Stochastic is 4 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NAGE PE vs Healthcare Sector
| Metric | NAGE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 22 | 29 | 7 pts below |
NAGE is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over NAGE on valuation relative to its sector.
NAGE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.50 | 15% below |
| 20 week MA | $2.93 | 27% below |
| 50 week MA | $4.14 | 49% below |
| 100 week MA | $6.23 | 66% below |
| 200 week MA | $4.35 | 51% below |
NAGE is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NAGE on trend strength, trading above more of its moving averages.
NAGE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.47 | $4.99 | +12% |
| 2021 | $4.99 | $4.13 | -17% |
| 2022 | $4.13 | $1.50 | -64% |
| 2023 | $1.50 | $1.43 | -4.7% |
| 2024 | $1.43 | $5.52 | +286% |
| 2025 | $5.52 | $6.64 | +20% |
| 2026 YTD | $6.64 | $2.13 | -68% |
NAGE's yearly returns have swung widely, from +286% in 2024 to −64% in 2022. It's down 68% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over NAGE on returns for 2026, with the stronger performance.